Related Experiment Videos
[Systematic lupus erythematosus and pregnancy].
Immunitat Und Infektion
|August 1, 1992
Summary
Systemic lupus erythematosus (SLE) activity during pregnancy is similar to nonpregnant patients and depends on disease onset. While pregnancy outcomes have improved, fetal loss risks persist due to antiphospholipid antibodies and SLE activity.
Area of Science:
- Rheumatology
- Obstetrics
- Immunology
Background:
- Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age.
- Historically, SLE exacerbation during pregnancy was widely believed, but recent evidence suggests similar activity levels in pregnant and nonpregnant individuals.
- Disease activity at conception is a key predictor of SLE behavior during pregnancy.
Discussion:
- Pregnancy outcomes in SLE patients have significantly improved.
- Fetal loss rates remain higher in SLE patients, primarily due to antiphospholipid antibodies, habitual abortions, intrauterine death, and premature labor.
- Monitoring complement proteins (CH50, C3, C4, C3d) aids in distinguishing SLE flares from eclampsia.
Key Insights:
- Prophylactic prednisone therapy for pregnant SLE patients is not recommended.
- Immunosuppressive therapy, including prednisone and potentially azathioprine, is indicated for active SLE during pregnancy.
- Low-dose aspirin may be considered for SLE patients with high antiphospholipid antibody titers and a history of fetal loss.
Outlook:
- Continued research into the mechanisms driving fetal loss in SLE is crucial.
- Personalized management strategies based on disease activity and antibody profiles can further improve pregnancy outcomes.
- Longitudinal studies are needed to fully understand the long-term effects of pregnancy on SLE progression.